Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Gareth Hughes et al.|The Lancet Oncology|2018Cited by 1k
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Inmaculada Ramos García, Byoung Chul Cho et al.|The Lancet Oncology|2018Cited by 579
The incidence and clinical impact of bone metastases in non-small cell lung cancerMichael Kuchuk, Paul Wheatley‐Price, Iryna Kuchuk et al.|Lung Cancer|2015Cited by 117
The Role of Palliative Chemotherapy in Hospitalized PatientsPaul Wheatley‐Price, C. Cripps, Maria Ali et al.|Current Oncology|2014Cited by 44
Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Non–Small-Cell Lung CancerPaul Wheatley‐Price, Brian C. Healy, Jason Pantarotto et al.|Clinical Lung Cancer|2014Cited by 15